期刊文献+

重组人骨形态发生蛋白-2缓释凝胶微球的研制及其溶胀、降解、载药、释药特征 被引量:3

Preparation of recombinant human bone morphogenetic protein-2 sustained release hydrogel microspheres, and in vitro studies of their swelling, biodegradation, drug loading and release
原文传递
导出
摘要 目的制备载人骨形态发生蛋白-2(rhBMP-2)的甲基丙烯酸缩水甘油酯右旋糖酐(dex-GMA)凝胶微球并初步考察其体外溶胀、降解、载药与释药特征。方法以液体石蜡为油相,Span-80为乳化剂,采用乳化化学交联技术制备载rhBMP-2的凝胶微球(BMP-HMs)并通过正交设计法优化其制备工艺;观察BMP-HMs形态和粒径,测定其包封率与载药量;用微球的吸水能力表示微球的溶胀率(Rs),扫描电镜观察微球的体外降解,动态观察体外释药特征及其与微球溶胀、降解的关系。结果所制备的BMP-HMs形态规整,粒径40~50μm,分布均匀;rhBMP-2载药量(10.6±4.8)%,包封率(88.9±1.0)%,BMP-HMs冻干剂4℃以下存放6个月性能稳定,但在磷酸盐缓冲液(PBS)中20~40d内可以完全降解。微球Rs随反应促进剂四甲基乙二胺(TEMED)用量的增大而减小,0.3mlTEMED制备的BMP-HMs体外释药实验表明80%的rhBMP-2在前20d左右释放。结论BMP-HMs对rhBMP-2具有确定的缓释作用,并可以通过制备工艺的改变控制其释药。 Objective To investigate the preparation method of recombinant human bone morphogenetic protein-2 (rhBMP-2) loaded dextran-based hydrogel microspheres (BMP-HMs) and evaluate their characteristics in swelling and biodegradation, drug loading and release. Methods By using liquid olefin as the oil phase and Span -80 as the emuifier, BMP-HMs were prepared by emulsion-chemical crosslink technique. The process of the recombination preparation was optimized by orthogonal factorization method. Then, the characteristics of BMP-HMs were evaluated by routine procedure. Swelling behavior was expressed by swelling ratio (Rs) and the size of BMP-HMs determined by electronic microscopy. The rhBMP-2 loading and encapsulation rate of BMP-HMs and their biodegradation characteristic were also studied. Dynamic dialysis was used to determine the release characteristic of BMP-HMs in vitro. Resuits BMP-HMs were homogenous and stable with the average diameter of 40-50 μm. rhBMP-2 loading and encapsulation rate was ( 10.6 ±4.8) % and (88.9 ± 1.0) %, respectively. Rs of BMP-HMs varied from 76% to 89% according to the amount of TEMED that was added at preparation of BMP-HMs. The in vitro experiment showed that 80% of rhBMP-2 could be released during the first 20 days, which could be controlled by Rs. Freeze-dried BMP-HMs could be kept under 4℃ for more than six months but be completely degradable in about 40 days in phosphate buffer solution (PBS). Conclusion As a new sustained release system of rhBMP-2, BMP-HMs exert definitive controlled release effect that can be controlled through change of the preparation technique.
出处 《中华创伤杂志》 CAS CSCD 北大核心 2005年第9期697-701,共5页 Chinese Journal of Trauma
基金 国家高技术研究发展计划资助项目(2002AA205041)
关键词 骨形态发生蛋白质类 右旋糖酐 微球体 控制释放 组织工程 重组人骨形态发生蛋白-2 体外降解 释药特征 胶微球 缓释作用 Bone morphogenetic proteins Dextran Microspheres Controlled release Tissue engineering
  • 相关文献

参考文献12

二级参考文献41

  • 1陈发明,吴织芬,金岩.牙周组织工程研究进展[J].中华口腔医学杂志,2004,39(6):520-522. 被引量:19
  • 2吴德升,赵定麟,何北平,杜晓冰.修复周围神经缺损的组织工程研究[J].生物医学工程学杂志,1997,14(2):108-110. 被引量:20
  • 3Yang L J, Jin L. Immunohistochemical observations on bone morphogenetic protein in normal and abnormal conditions[ J ]. Clin Orthop,1990, 257: 249-56.
  • 4Kawamura M, Urist MR. Human fibrin is a physiologic delivery system for bone morphogenetic protein[J]. Clin Orthop, 1988, 235: 302-10.
  • 5Maysinger D, Krieglstein K, Filipovic G J, et al. Microencapsulated ciliary nourotrophic factor: physical properties and biological activities[J]. Exp Neurol, 1996, 138(2): 177-88.
  • 6Hiraki Y, Inoue H, Shigeno C. Bone morphogenetic protein (BMP-2 and BMP-3) promote growth and expression of the differentiated phenotype of rabbit chondrocytes and osteoblastic MC3T3-E1 cell in vitro[J]. J Bone Miner Res, 1991, 6(12): 1373-85.
  • 7Cook SD, Dalton JE, Tan EH, et ol. In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions[J]. Spine, 1994, 19(15): 1655-63.
  • 8Groot JD. Carriers that concentrate native bone morphogenetic protein in vivo[J]. Tissue Eng, 1998, 4(4): 337-41.
  • 9Lee EO, Kim JD. Palmitoyl lysozyme-induced stabilization of PE(phosphatidylethanolamine) liposomes and their interaction with Candida albicans[J]. J Biochem, 1995, 117(1): 54-8.
  • 10Rodriguez ML, Holgado MA, Sanchez LC, et al. Alginatc/chitosan particulate systems for sodium diclofenac release[J]. Int J Pharm,2002, 232(1-2): 225-34.

共引文献52

同被引文献32

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部